Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000557446 | SCV000625935 | likely benign | Duchenne muscular dystrophy | 2024-10-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000766086 | SCV000897561 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Dilated cardiomyopathy 3B | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002367771 | SCV002661202 | uncertain significance | Cardiovascular phenotype | 2023-03-21 | criteria provided, single submitter | clinical testing | The p.E2137Q variant (also known as c.6409G>C), located in coding exon 44 of the DMD gene, results from a G to C substitution at nucleotide position 6409. The glutamic acid at codon 2137 is replaced by glutamine, an amino acid with highly similar properties. Based on data from gnomAD, the C allele has an overall frequency of 0.002% (5/203204) total alleles studied, including one hemizygote. The highest observed frequency was 0.02% (4/18954) of African alleles. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001834733 | SCV002090328 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2018-06-11 | no assertion criteria provided | clinical testing |